Combining donepezil with cognitive training to help reduce heavy drinking in people with alcohol use disorder
Official title: The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
Run by VA Connecticut Healthcare System · NCT05042102 · Data updated 2026-11-12
This study is testing if a combination of a medication called donepezil and cognitive training can help people with alcohol use disorder drink less.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | VA Connecticut Healthcare System Federal |
| Locations | 1 site (West Haven, Connecticut) |
| Status | Recruiting |
| Started | August 8, 2022 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT05042102 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-80 who meet the criteria for alcohol use disorder and have experienced heavy drinking within the past month.
✕Probably not a fit
Patients with a history of psychotic disorders or those currently using opioids or benzodiazepines may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of donepezil combined with cognitive remediation therapy in reducing heavy drinking among patients diagnosed with alcohol use disorder. Participants will be randomly assigned to receive either the active treatment or a placebo in a double-blind manner. The study will assess the outcomes over a 13-week period, focusing on changes in drinking behavior and cognitive function. The trial includes both medication and therapy components to explore their combined effects on alcohol use disorder.
Why it matters
Potential benefit: If successful, this approach could provide a new treatment option for individuals struggling with alcohol use disorder, potentially leading to reduced drinking and improved cognitive function.
How similar studies have gone: While the combination of donepezil and cognitive training is a novel approach, similar studies exploring cognitive interventions for alcohol use disorder have shown promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Males and females 18-80 years of age 2. Fluency in English and a 6th grade or higher reading level 3. Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current alcohol use disorder (subjects should have a primary alcohol use disorder \[AUD\] diagnosis, but may have concurrent occasional use of other substances) 4. Last alcohol use and at least one heavy drinking day within the past 30 days 5. Willingness to attend follow-up assessments at 13 weeks 6. Willingness to submit to Urine Toxicology screenings Exclusion criteria: 1. Lifetime diagnosis of a psychotic disorder, not induced by drug use 2. Current treatment with opioids or benzodiazepines, which may affect new learning 3. Involvement in a legal case that may lead to incarceration during the study period 4. Residential plans that would interfere with participation 5. Medical illness that may significantly compromise cognition (e.g., Parkinson's, Alzheimer's, Huntington's chorea, moderate or greater TBI) 6. An uncorrected sensory impairment (hearing or sight) that would seriously interfere with cognitive training 7. Pre-morbid intelligence quotient (IQ) estimate below 70 8. Unstable housing or lack of commitment to staying within a geographic area that would make follow-up unlikely 9. Unwillingness to provide contact information of someone who can help study staff contact the subjects in the event that study staff are unable to maintain contact directly 10. Allergy to donepezil 11. Unstable cardiovascular disease or unstable medical condition-clinically determined by a physician 12. Imminent suicidal or homicidal risk 13. Pregnant or nursing women, positive pregnancy test, or inadequate birth control methods in women of childbearing potential
Where it's running
-
VA Connecticut Healthcare System
West Haven, Connecticut, United States Recruiting
Study contacts
- Principal investigator: Gihyun Yoon, MD — Yale University, VA Connecticut Healthcare System
- Study coordinator: Gihyun Yoon, MD
- Email: gihyun.yoon@yale.edu
- Phone: 203-932-5711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Thiamine to reduce brain injury in adults with alcohol use disorder
This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.
-
Digital Recovery Support for Black adults with Alcohol Use Disorder in Detroit
This study tests whether a smartphone-based digital recovery program helps Black or African American adults in Detroit maintain their recovery from alcohol use disorder.
-
Path180: a computer-based skills program to help teens reduce alcohol use
This 8-week trial tests Path180, a computer-based skills training, added to usual care for teens 13–19 with alcohol use disorder to see if it improves daily-life coping skills and outcomes.
-
Effects of comorbidity on people with severe mental illness
This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.
-
Psilocybin in Alcohol Use Disorder with Depression (Relapse Prevention)
This study tests whether higher-dose psilocybin-assisted psychotherapy helps prevent relapse in adults with severe alcohol use disorder and depressive symptoms after detox.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.